GNTbm Unveils Promising Preclinical Findings for GNTbm-TKI at ESMO 2025 GNTbm has introduced preclinical results for its innovative GNTbm-TKI, a multi-targeted tyrosine kinase inhibitor aimed at enhancing cancer immunotherapy, at ESMO 2025.

GNTbm Unveils Promising Preclinical Findings for GNTbm-TKI at ESMO 2025 #Taiwan #Taipei #Cancer_Immunotherapy #GNTbm-TKI #Advanced_Oncology